en · de · es · fr · pt
tb-500-notes.peptides5388.com › Guide › Tb-500 Identity And Molecular Background — Practical Notes

Tb-500 Identity And Molecular Background — Practical Notes

By Editorial Desk · published 2025-09-22 · last reviewed 2025-10-31 · Guide

The short version of Ac-LKKTETQ fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Related pages on this site

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Handling Storage And Analysis

Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.

Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.

Detection, Stability, and Regulatory Status

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Reference notes

== Behaviour and ecology == Like other snakes, a king cobra receives chemical information via its forked tongue, which picks up scent particles and transfers them to a sensory receptor (Jacobson's organ) located in the roof of its mouth. Following envenomation, it swallows its prey whole. Because of its flexible jaws, it can swallow prey much larger than its head. It is considered diurnal because it hunts during the day, but has also been seen at night, albeit rarely.

=== Leukemia === Leukemia, a cancer of the blood or bone marrow, is characterized by an abnormal increase of immature white blood cells. The risk of childhood leukemia is increased, as demonstrated in a Chinese case–control study, and the risk increases with length of treatment.

Railway transport in Malaysia is state-run, and spans some 2,783 kilometres (1,729 mi). As of 2016, Malaysia has the world's 26th-largest road network, with some 238,823 kilometres (148,398 mi) of roads. Malaysia's inland waterways are the world's 22nd-longest, and total 7,200 km (4,474 mi). Among Malaysia's 114 airports, the busiest one is Kuala Lumpur International Airport (KLIA), located in the Sepang District; it is also the 12th-busiest airport in Asia. Among the seven federal ports, the major one is Port Klang, which is the 13th-busiest container port. Malaysia's flag carrier is Malaysia Airlines, providing international and domestic air services. Malaysia's telecommunications network is second only to Singapore's in Southeast Asia, with 4.7 million fixed-line subscribers and more than 30 million cellular subscribers. There are 200 industrial parks along with specialised parks such as Technology Park Malaysia and Kulim Hi-Tech Park. Fresh water is available to over 95% of the population, with groundwater accounting for 90% of the freshwater resources. Although rural areas have been the focus of great development, they still lag behind areas such as the West Coast of Peninsular Malaysia. The telecommunication network, although strong in urban areas, is less available to the rural population. Malaysia's energy infrastructure sector is largely dominated by Tenaga Nasional, the largest electric utility company in Southeast Asia. Customers in Peninsular Malaysia are connected to electricity through the National Grid.

There were some issues with this survey though. The NCVS produces only the annual estimates of victimization. The survey that Christi Guerrini, Jill Robinson, Devan Petersen, and Amy McGuire produced asked the participants about the incidents of victimization over one's lifetime. Their survey also did not restrict other family members to one household. Around 25% of people who responded to the survey said that they have had family members that have been employed by law enforcement which includes security guards and bailiffs. Throughout these surveys, it has been found that there is public support for law enforcement to access genetic genealogy databases.

The Stanley Parable - An interactive fiction modification, with multiple endings depending on decisions made by the player. Similar to Dear Esther, the mod was developed into a full commercial release in 2013. Thinking with Time Machine - A mod built atop Portal 2, which adds in the ability for the player to create a brief recording of their actions and then interact with that recording on its playback, including the use of portals.

Sources: en.wikipedia.org

Notes from published material

What is behavior? Baby don't ask me, don't ask me, no more at Earthling Nature. behaviorinformatics.org Links to review articles by Eric Turkheimer and co-authors on behavior research Links to IJCAI2013 tutorial on behavior informatics and computing

Bully: Kevin Garcia Height: 5'11 Weight: 175 lbs. Victim(s): Anthony (co-worker) and Sam Fighter: Tyron Woodley Height: 5'9 Weight: 182 lbs. Money earned by Bully: $1,000 Money earned by victim(s): $9,000 Original airing:

== Occurrence == The occurrence of unsaturated fats varies widely in nature. The saturated fatty acid components are almost exclusively stearic (C18) and palmitic acids (C16). Monounsaturated fats are almost exclusively oleic acid. Linolenic acid comprises most of the triunsaturated fatty acid component.

During the First World War (1914–1918), and for a short period afterwards, there were at least 250 recognised airfields in France that the Royal Flying Corps, Royal Naval Air Service, and Royal Air Force used at various times.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network